R. Moriggl

A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia

This paper creates a mouse model with a STAT5BN642H mutation to study NK-cell leukemia and finds it leads to both indolent and aggressive forms of the disease.

JUN mediates senescence and immune cell recruitment to prevent prostate cancer progression

This study shows JUN suppresses prostate cancer progression by inducing senescence and immune cell recruitment, with JUN depletion accelerating tumor growth.

Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma

This study evaluates small molecule STAT3/5 inhibitors for treating AML and NKCL, showing growth arrest and synergy with existing therapies in vitro and in vivo.

STAT5 Gain-of-Function Variants Promote Precursor T-Cell Receptor Activation to Drive T-Cell Acute Lymphoblastic Leukemia

This study identifies STAT5 gain-of-function mutations as drivers of T-ALL by promoting pre-TCR signaling and shows therapeutic targeting potential with STAT3/5 or ZAP70 inhibitors.

STAT3 restricts prostate cancer metastasis and antiandrogen resistance by controlling LKB1/CREB signaling pathway

This study identifies STAT3's role in restricting prostate cancer metastasis and antiandrogen resistance by regulating the LKB1/CREB signaling pathway in mouse models and human patients.

STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pigmentation pathway

This study shows that STAT3 promotes melanoma metastasis by repressing the MITF pigmentation pathway through CEBP induction.

Oncogenic GLI1 and STAT1/3 activation drives immunosuppressive tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin cancer cells

This study identifies IDO1-kynurenine pathway activation as a novel mechanism by which HH-IL6 and GLI-STAT signaling promote immunosuppression in skin cancer, suggesting combination therapy targeting these pathways.

Thyroid and androgen receptor signaling are antagonized by CRYM in prostate cancer

This study shows that CRYM antagonizes thyroid and androgen signaling in prostate cancer and correlates with prognosis and PET imaging biomarkers.

The neonatal microenvironment programs conventional and intestinal Tbet+ γδT17 cells through the transcription factor STAT5

This study shows STAT5 is critical for neonatal expansion of γδT17 cells, which acquire tissue-specific traits necessary for immunity and autoimmunity.

The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

This study identifies the ERBB-STAT3 axis as a driver of Tasmanian devil facial tumor disease and proposes a dual chemo-immunotherapeutic strategy.